Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,11 +2,9 @@
2	2	(((
3	3	(% class="container" %)
4	4	(((
5		-= **Neurodiagnoses**
6		-//A new tridimensional diagnostic framework for CNS conditions// =
	5	+= Neurodiagnoses =
7	7
8		-This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
9		-We aim to create a structured, interpretable, and scalable diagnostic tool.
	7	+This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
10	10	)))
11	11	)))
12	12
...	...	@@ -14,72 +14,14 @@
14	14	(((
15	15	(% class="col-xs-12 col-sm-8" %)
16	16	(((
17		-= What is this about and what can I find here? =
	15	+= What can I find here? =
18	18
19		-==== **Overview** ====
	17	+* `/docs`: Documentation and contribution guidelines.
	18	+* `/code`: Machine learning pipelines and scripts.
	19	+* `/data`: Sample datasets for testing. - `/outputs`: Generated models, visualizations, and reports.
20	20
21		-The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
	21	+= Who has access? =
22	22
23		-* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
24		-* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
25		-* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
26		-
27		-This methodology enables:
28		-
29		-* Greater precision in diagnosis.
30		-* Integration of incomplete datasets using AI-driven probabilistic modeling.
31		-* Stratification of patients for personalized treatment.
32		-
33		-==== **Diagnostic Axes** ====
34		-
35		-* (((
36		-**Axis 1: Etiology**
37		-
38		-* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
39		-* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
40		-* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
41		-)))
42		-* (((
43		-**Axis 2: Molecular Markers**
44		-
45		-* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
46		-* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
47		-* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
48		-)))
49		-* (((
50		-**Axis 3: Neuroanatomoclinical**
51		-
52		-* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
53		-* //Examples//: Hippocampal atrophy correlating with memory deficits.
54		-* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
55		-)))
56		-
57		-==== **Case Studies** ====
58		-
59		-1. (((
60		-**Sporadic Alzheimer’s Disease**:
61		-
62		-* Axis 1: Sporadic (ApoE4, poor sleep habits).
63		-* Axis 2: Amyloid-beta plaques, elevated NFL.
64		-* Axis 3: Right hippocampus atrophy (visual memory loss).
65		-)))
66		-1. (((
67		-**Genetic Parkinson’s Disease**:
68		-
69		-* Axis 1: Genetic (LRRK2 mutation).
70		-* Axis 2: Alpha-synuclein aggregation.
71		-* Axis 3: Substantia nigra degeneration (motor dysfunction).
72		-)))
73		-
74		-==== **Applications** ====
75		-
76		-This system enhances:
77		-
78		-* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
79		-* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
80		-
81		-== Who has access? ==
82		-
83	83	We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
84	84
85	85	== How to Contribute: ==
...	...	@@ -87,12 +87,6 @@
87	87	* Access the `/docs` folder for guidelines.
88	88	* Use `/code` for the latest AI pipelines.
89	89	* Share feedback and ideas in the wiki discussion pages.
90		-
91		-== Key Objectives: ==
92		-
93		-* Develop interpretable AI models for diagnosis and progression tracking.
94		-* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
95		-* Foster collaboration among neuroscientists, AI researchers, and clinicians.
96	96	)))
97	97
98	98
...	...	@@ -102,11 +102,11 @@
102	102	{{toc/}}
103	103	{{/box}}
104	104
105		-== Main contents: ==
	39	+== Key Objectives: ==
106	106
107		-* `/docs`: Documentation and contribution guidelines.
108		-* `/code`: Machine learning pipelines and scripts.
109		-* `/data`: Sample datasets for testing.
110		-* `/outputs`: Generated models, visualizations, and reports.
	41	+* Develop interpretable AI models for diagnosis and progression tracking.
	42	+* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
	43	+* Foster collaboration among neuroscientists, AI researchers, and clinicians.
	44	+
111	111	)))
112	112	)))